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Communicated by Claude Feréc 
Lafora disease (LD) is a fatal form of teenage-onset autosomal recessive progressive 
myoclonus epilepsy. LD is more common among geographic isolates and in populations with 
a higher rate of consanguinity. Mutations in two genes, EPM2A encoding laforin 
phosphatase, and NHLRC1 encoding malin ubiquitin ligase, have been shown to cause the 
LD. We describe here a systematic analysis of the EPM2A and the NHLRC1 gene sequences 
in 20 LD families from the Indian population. We identified 12 distinct mutations in 15 LD 
families. The identified novel mutations include 4 missense mutations (K140N, L310W, 
N148Y, and E210K) and a deletion of exon 3 for EPM2A, and 4 missense mutations (S22R, 
L279P, L279P, and L126P) and a single base-pair insertional mutation (612insT) for 
NHLRC1. The EPM2A gene is known to encode two laforin isoforms having distinct 
carboxyl termini; a major isoform localized in the cytoplasm, and a minor isoform that 
targeted the nucleus. We show here that the effect of the EPM2A gene mutation L310W was 
limited to the cytoplasmic isoform of laforin, and altered its subcellular localization. We 
have also analyzed the impact of NHLRC1 mutations on the subcellular localization of malin. 
Of the 6 distinct mutants tested, three targeted the nucleus, one formed perinuclear 
aggregates, and two did not show any significant difference in the subcellular localization as 
compared to the wild-type malin. Our results suggest that the altered subcellular localization 
of mutant proteins of the EPM2A and NHLRC1 genes could be one of the molecular bases of 
the LD phenotype © 2008 Wiley-Liss, Inc. 
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INTRODUCTION 
Lafora disease (LD; MIM# 254780) is an autosomal recessive and fatal form of progressive myoclonus epilepsy 
characterized by the presence of polyglucosan inclusions, called Lafora bodies (Delgado-Escueta et al., 2001; 
Ganesh et al., 2006). The symptoms of LD usually begin in late childhood or adolescence and become 
progressively severe. In addition to grand mal, tonic–clonic, and absence seizures, neurological deficits like 
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cerebellar ataxia, psychosis, and quickly developing dementia are commonly seen in LD (Delgado-Escueta et al., 
2001; Ganesh et al., 2006; Sinha et al 2007). Defects in at least three genes underlie LD, of which two have been 
isolated and their mutations characterized: The EPM2A gene (MIM# 607566) encoding laforin (Minassian et al., 
1998; Serratosa et al., 1999; Ganesh et al., 2000) and the NHLRC1 gene (MIM# 608072) encoding malin (Chan et 
al., 2003). Laforin is a protein phosphatase, which is ubiquitinated by malin before degradation (Ganesh et al., 
2000; Gentry et al., 2005; Lohi et al., 2006; Mittal et al., 2007). Aberrant functions of laforin and/or malin, which 
eventually affect the post-translational modification of target proteins, are likely to underlie the onset and 
progression of LD (Ganesh et al., 2006; Mittal et al., 2007).  
LD, although relatively rare in the out bred populations of the United States, Canada, China and Japan, is 
commonly encountered in the Mediterranean basin of Spain, France, and Italy, in restricted regions of central Asia, 
south Asia, northern Africa, the Middle East, in ethnic isolates from the southern United States (Spanish descents) 
and Quebec, Canada (French descents) (Delgado-Escueta et al., 2001; Ganesh et al., 2006). As expected, LD is 
common among populations where a high rate of consanguinity is practiced. Among the populations studied, the 
Indian subcontinent appears to have a higher frequency of LD, especially in the southern states of India (Acharya 
et al., 1993, 1995; Sinha et al., 2007). Interestingly, the spectrum of mutations and the associated gene appears to 
differ among LD populations: While EPM2A is more often mutated in the Spanish population, it is defects in the 
NHLRC1 gene that are the common cause for LD in Italian population (Singh et al., 2006). Large deletions in the 
EPM2A gene appear to be common among the LD patients from the Middle East (Gomez-Abad et al., 2007). 
However, no systematic study has been carried out to evaluate mutational spectrum and locus heterogeneity for LD 
in Indian population. Here we report the mutation screening of EPM2A and NLHCR1 genes in 20 LD families from 
Indian population and results of functional studies on the mutations identified. 
MATERIALS AND METHODS 
Patients 
We studied 20 unrelated Indian families affected with LD. The diagnosis of LD was based on clinical data 
including the skin biopsy staining for Lafora bodies. Informed consent to participation in the study was obtained 
from the patients or their parents. This study was approved by the institutional review board of participating 
centers. 
Mutational screening 
Genomic DNA was extracted from the blood samples using a QIAamp blood DNA purification kit (Qiagen Inc, 
Valencia, California, USA) or from the tissue biopsies using a Nucleon DNA extraction kit (GE Healthcare, USA). 
The coding regions of the EPM2A and NHLRC1 genes were polymerase chain reaction (PCR) amplified using 
established primers (Ganesh et al., 2002; Singh et al., 2005, 2006), directly sequenced using the DTCS QuickStart 
sequencing kit (Beckman Coulter, Fullerton, California, USA) on a CEQ800 automated DNA sequencer (Beckman 
Coulter), and analyzed using CEQuence investigator module (Beckman Coulter). DNA mutation numbering was 
based on GenBank reference sequences NM_005670.3 (for EPM2A) and NM_198586.2 (for NHLRC1) by 
considering the A of the ATG translation initiation codon as +1. 
In vitro expression studies 
The expression construct pcDNA-EPM2A encoding the laforin protein with carboxyl terminal Myc-tag and 
pEGFP-NHLRC1 encoding enhanced green fluorescent protein (EGFP)-malin fusion protein (Mittal et al, 2007) 
were used for the transfection studies. Point mutation in the EPM2A coding region was generated by using the site-
directed mutagenesis as described (Ganesh et al., 2000). For NHLRC1 mutant constructs, the coding region was 
amplified from the genomic DNA of the affected and cloned in-frame in the pEGFP-C2 vector. Transfection of 
constructs expressing mutant proteins in COS-7 cells were performed in parallel and subcellular localization was 
evaluated as described elsewhere (Mittal et al., 2007). In brief, COS-7 cell line was grown in Dulbecco's modified 
Eagle's medium (Sigma-Aldrich Chemicals Pvt Ltd, India) at 37°C in 5% CO2 and supplemented with 10% 
(vol/vol) fetal calf serum, 100 U/ml penicillin and 100 µg/ml streptomycin. Cells were transiently transfected with 
expression constructs using the ESCORT V transfection reagent (Sigma-Aldrich Chemicals Pvt Ltd, India) and 
processed for examination at 36 hours post transfection. Cells, fixed in 2% paraformaldehyde, were incubated with 
10 µM 4',6-diamidino-2-phenylindole (DAPI) for 5 min subsequent to secondary antibody incubation. 
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Fluorescence images were obtained using a fluorescence microscope (AxioScope 2 plus, Carl Zeiss, Germany) 
with 40x objective lens and were processed using Axiovision software (Carl Zeiss, Germany). 
For ummunoblotting, protein samples were run on a 10% SDS–PAGE and transferred onto a nitrocellulose filter 
(MDI, India) as described previously (Mittal et al., 2007). After blocking with 5% non-fat dry milk powder, the 
membranes were processed through sequential incubations with primary antibody followed by secondary antibody. 
Immunoreactive proteins on the filter were visualized using a chemiluminscent detection kit (SuperSignal West 
PICO, Pierce, USA). 
Immunofluorescence and immunoblotting were done using either the anti-Myc antibody (Sigma-Aldrich 
Chemicals Pvt Ltd) or the anti-GFP antibody (Sigma-Aldrich Chemicals Pvt Ltd). For experiments, cells were 
double stained using anti-ribosomal protein (Santa Cruz Biotechnology Inc, USA). Secondary antibodies were 
obtained from Jackson Immuno Research (USA). 
RESULTS 
Genomic DNA from 20 unrelated Indian patients affected by LD was screened for nucleotide variants. Patients 
representing eight independent families had nucleotide variations in the coding region of the EPM2A gene and 
seven had mutations in the NHLRC1 gene. None of the patients screened showed mutations in both genes and none 
of the variations identified were observed in the DNA of 100 individuals from the unaffected population. 
Mendelian inheritance of mutations was confirmed in families when the DNA samples of parents were available. 
Mutations identified in the present study have been submitted to the Lafora progressive myoclonus epilepsy 
mutation and polymorphism database (Ianzano et al., 2006) (http://projects.tcga.ca/lafora/).  
EPM2A gene mutations 
Patient DNA-22 revealed the presence of the point mutation c.412G>T in homozygosis resulting in the 
previously known nonsense mutation p.E138X (Minassian et al., 1998) while patient 260 presented the c.442A>T 
in homozygosity with a novel missense mutation p.N148Y (see Table 1 and Figure 1). Patients LDI-M was a 
compound heterozygote for two different missense mutations: (i) a G to C transversion at nucleotide 420 that is 
responsible for converting a lysine to an asparagine acid residue at amino acid position 140 (p.K140N) and (ii) a T 
to G transversion at nucleotide 929 that is responsible for converting a leucine to a tryptophan residue at amino 
acid position 310 (p.L310W) (Figure 1). Curiously, four unrelated patients (T30, T8, T9 and T7) shared the same 
mutation in the EPM2A gene (deletion of exon 3) and three of them belong to southern part of India and one from 
the western part of the country (Figure 2). This deletion is predicted to change the reading frame of the EPM2A 
transcripts and affect the dual-specificity phosphatase domain of laforin protein (Figure 1). Patient DNA18 carried 
a novel missense mutation (p.E210K), resulting from the G to A transition at 628 nucleotide position, in 
heterozygosis in the EPM2A gene. The residues affected by the 4 missense mutations identified in the present 
study are highly conserved across laforin orthologues, reflecting the evolutionary constraints placed on these 
residues (Figure 1). Only one, however, affected the known functional domain of laforin (p.E210K in the dual-
specificity phosphatase domain) (Figure 1).  
Effect of mutation p.L310W is limited to the cytoplasmic isoform of laforin 
Differential splicing in the EPM2A transcript is known to result in the generation of two distinct laforin 
isoforms: A 331 amino acid long major isoform of laforin that targets the rough endoplasmic reticulum (Ganesh et 
al., 2000), and a 317 residue long minor isoform of laforin with a unique carboxyl terminal end and targeting the 
nucleus (Ganesh et al., 2002) (see Figure 3). Curiously, the effect of missense mutation p.L310W identified in the 
present study is limited to the cytoplasmic major isoform because this mutation is intronic in the transcript that 
encodes the 317-residue minor laforin (Figure 3). We therefore tested the effect of this mutation on the subcellular 
localization of laforin-331. Laforin-331 is known to localize in the cytoplasm, along side the endoplasmic 
reticulum (Ganesh et al., 2000). To evaluate the effect of p.L310W mutation on laforin-331 localization, we 
transiently  expressed  the mutant  protein,  with  a  C-terminal  Myc-epitope,  in  COS-7  cells  and  detected using  
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Table 1:  Summary of the identified EPM2A and NHLRC1 gene mutations in the Indian Lafora disease families 
Family* Nucleotide change and 
predicted effect+
Exon/ 
domain 
affected 
Mutation 
state@
Age at 
onset of 
seizures 
(years) 
Major symptoms (in 
chronological order of 
appearance)$
The EPM2A gene 
LDI-M (2) c.420G>C; p.K140N 
c.929T>G; p.L310W 
Exon 2 
Exon 4 
Comp 
het 
GTCS - 13 
 
GTCS, ataxia, cognitive 
decline 
260 (1) c.442A>T; p.N148Y Exon 2 Homo (?) GTCS - 11 
MJ - 17 
GTCS, MJ, cognitive 
decline, visual disturbances, 
behavioral problems and 
ataxia 
T30 (2) # c.476-?_718+?; R159fsX65  
(Deletion of exon 3) 
Exon 3 Homo MJ - 5 MJ 
T8 (1) # c.476-?_718+?; R159fsX65  
(Deletion of exon 3) 
Exon 3 Homo MJ - 10  Cognitive decline, and MJ 
T9 (1) # c.476-?_718+?; R159fsX65  
(Deletion of exon 3) 
Exon 3 Homo NA NA 
T7 (1) # c.476-?_718+?; R159fsX65  
(Deletion of exon 3) 
Exon 3 Homo GTCS - 12  
MJ - 12 
Cognitive decline, GTCS, 
and MJ 
DNA18 (1) c.628G>A; p.E210K Exon 2 Hetero MJ - 17 
GTCS - 19 
MJ, GTCS, cognitive 
decline, behavioral problems 
and visual  disturbances 
DNA22 (1) c.412G>T; p.E138X Exon 3 Homo NA NA 
The NHLRC1 gene 
258 (1) c.64A>C;  p.S22R Close to 
RING 
Homo (?) MJ - 13 Cognitive decline, and MJ 
292 (1) c.836T>C; p.L279P NHL (4th) Homo GTCS - 13 
MJ - 14 
GTCS, MJ  
SA (1) c.468-469delAG; 
p.156Gfs173 
NHL 
(2-6th) 
Homo GTCS – 13 
MJ - 13 
GTCS, MJ 
301 (1) c.836T>C; p.L279P NHL (4th) Homo GTCS - 9 
MJ - 14 
GTCS, MJ, cognitive decline 
and behavioral problems 
DNA9 (1) c.612insT; p.F205fs232 NHL  
(3-6th) 
Homo NA NA 
T27 (1) c.676C>T; p.Q226X NHL 
(3-6) 
Homo GTCS - 16 
MJ - 17 
GTCS, MJ, cognitive 
decline, ataxia, and 
behavioral problem  
266 (1) c.377T>C; L126P NHL (1st) Homo GTCS - 9 
MJ - 10 
GTCS, MJ, cognitive 
decline, visual disturbances, 
and behavioral problem  
Homo, homozygous; Hetero, heterozygous; Comp het, compound heterozygous; MJ, myoclonic jerks; GTCS, grandmal 
tonic clonic seizures; NA, information not available; RING/NHL, functional domains of malin  
*Number within the parentheses indicates number of affected individuals in that family 
#Tested negative for Lafora bodies in skin biopsy 
@Question mark within parentheses (?) denotes mutation state as inferred from the analysis parents’ DNA. 
$Follow up period varied between 1 to 5 years; hence data given here are not complete for all patients. 
+DNA mutation numbering is based on GenBank reference sequences NM_005670.3 (for EPM2A) and NM_198586.2  
(for NHLRC1) by considering the A of the ATG translation initiation codon as +1. 
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Figure 1 : Schematic diagram showing domain organization of laforin (a), and malin (b) proteins, and the 
positions of various mutations found in the Indian LD families. CBD, DSPD, RING and NHL refer to 
carbohydrate-binding domain, dual-specificity phosphatase domain, RING domain, and NHL repeats, 
respectively. The genomic structure (exon-intron organization) of the EPM2A gene is shown below figure a. 
In figures c and d, the evolutionary conservation of amino acid residues altered by missense mutations in 
laforin and malin are shown. A comparison of amino acids and the flanking sequence altered by the five 
unique missense mutations in human (Hs), mouse (Mm), rat (Rn), chicken (Gg), and dog is depicted. The 
mutated amino acid residue is shown in bold font and the resulting mutation is shown in bottom. 
ct immunoblotting and immunofluorescence approaches (Figure 4). Unlike the wild-type laforin-331, laforin 
nt p.L310W formed punctate cytoplasmic aggregates adjacent to the nucleus in great majority of the cells, 
sting that the mutation has impaired the subcellular targeting of laforin-331 (Figure 4). 
RC1 gene mutations 
quence analysis of the NHLRC1 gene revealed 4 novel mutations, of which three were missense mutations 
re 1). Two of these mutations (p.L279P and p.L126P) predicted to affect the NHL domains of malin whereas 
p.S22R) fell very close to the RING finger domain (Figure 1). The missense mutation p.L279P was shared by 
nrelated patients (patient 292 and 301) and the affected showed comparable clinical phenotypes (Table 2). 
hree residues affected by the missense mutations were conserved across malin orthologues compared, 
sting the functional importance of these residues (Figure 1). The nonsense mutation (p.Q226X) and the two 
shift mutations (p.G156fs173 and p.F205fs232) predicted to result in a truncated and nonfunctional malin 
in lacking three or more NHL repeats at its carboxyl terminal (Table 2, and Figure 1). The two-base pair 
ion allele (c.468-469delAG), resulting in the frameshift mutation p.G156fs173 in malin, was earlier reported  
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Figure 2 : Map showing deletion breakpoints for exon 3 of the 
EPM2A gene in 4 Indian LD families (T30, T8, T7, and T7) as 
refined by PCR analysis. The genomic organization of exons 1-4 
(open boxes) of the EPM2A gene is indicated. Open square, 
unaffected male; filled symbol, affected individual. “Control” 
refers to a wild-type sample 
 
in the Brazilian and Italian populations (Chan et al., 2003), suggesting that this could be a recurrent mutation and 
hence a mutational hotspot.  
Effect of NHLRC1 mutations on malin’s cellular localization 
We have recently reported that LD associated malin mutants form cytoplasmic aggregates known as 
aggresomes (Mittal et al., 2007). We therefore evaluated the effect of NHLRC1 mutations identified in the present 
study on the subcellular localization of malin. For this, we transiently expressed the wild-type or mutant forms of 
malin in COS-7 cells and examined their expression and subcellular localization. For this study, six mutants were 
chosen of which two had mutation in the RING domain and all other affected the NHL repeat domains (Figure 1). 
The expression constructs encoding GFP-tagged malin and the six mutant forms produced fusion proteins of 
expected size (Figure 5), suggesting that the computational prediction of the altered coding region was accurate. 
The effect of LD-associated malin mutations on cellular localization was found to be more diverse; mutations 
S22R and F205fs232 did not significantly alter the localization of the mutant forms as compared to the wild-type 
malin (Figure 6). However, mutation L279P, which affected the 4th NHL repeat, had significantly altered the malin 
distribution as a great majority of cells expressing the mutant form formed perinuclear inclusion when compared 
with the wild-type form (Figure 6). For mutations L126P, Q226X, and G156fs173, the mutant malin targeted 
exclusively nucleus as compared to predominantly cytoplasmic and partially nuclear localization of the wild-type 
malin (Figure 6). Mutant L126P though had a small fraction of the malin going to the cytoplasm. Western blotting 
of cell lysates did not show any significant difference in the level of expression between the mutants for malin, or 
when compared to the wild-type malin, suggesting that the subcellular localization pattern was not associated with 
differential expression level for malin mutants. 
Five LD families did not show mutations in the EPM2A and NHLRC1 genes 
Direct sequencing of the coding regions and about 50 bases of flanking intronic sequences of the EPM2A and 
NHLRC1 genes revealed no mutations in the affected individuals from 5 independent families clinically diagnosed 
to have LD.  
DISCUSSION 
In this report, we describe a systematic analysis of the EPM2A and NHLRC1 gene sequences in 20 LD families 
from the Indian population. Of the 12 mutations identified in the present study, 9 are novel mutations. These 
include 4 missense mutations (K140N, L310W, N148Y, and E210K) and the exon 3 deletion mutation for the 
EPM2A gene, and 4 missense mutations (S22R, L279P, L279P, and L126P) and a single base-pair insertion 
mutation (612insT) for the NHLRC1 gene. The exon-3 homozygous deletion observed for the EPM2A gene in 4 
independent LD families suggests that this mutation could be novel to the Indian populations. Larger deletions in 
the EPM2A gene have been observed in many populations (American, Arabic and Caucasian) but all such deletions 
were restricted to the exon 2 or the exon 1-2 combined regions (Minassian et al., 1998; Serratosa et al., 1999; 
Minassian et al., 2000; Gomez-Garre et al., 2000; Ganesh et al., 2002; Ganesh et al., 2006; Gomez-Abad et al., 
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2007). The present study suggests that such deletions need not be restricted to a few exons of the gene. We also 
note that the two nonsense mutations (E138X, and Q226X) and the 2-basepair deletion (c.468-469delAG) mutation 
identified in the present study are reported in the literature (Chan et al., 2003), and hence appear to be recurrent 
mutations. 
In our screening of 20 Indian LD families, 8 families (40%) had mutations in EPM2A, and 7 families (35%) had 
mutations in the NHLRC1 gene. In 5 families (25%) no mutations were seen in either of the two genes screened. 
Our data therefore suggest that EPM2A and NHLRC1 are the major genes for LD in Indian population, 
representing ~75% of the families studied for genetic defects. Since the clinical follow ups of the Indian LD 
patients are not complete and exhaustive, we are unable to compare the phenotype of patients having the EPM2A 
mutations with those that are defective for NHLRC1 or those who did not show mutations in either of the two 
genes screened. Available clinical data however did not reveal any significant difference in the age at onset and/or 
in the symptoms between the patients belonging to the three genotype groups. A rigorous follow up study would 
help us to uncover whether or not NHLRC1 patients show a slower rate of disease progression as seen in the 
Caucasian populations (Gomez-Abad et al., 2005; Singh et al., 2006; Franceschetti et al., 2006). 
Mutational screening for the coding regions of the EPM2A and NHLRC1 genes revealed no sequence changes in 
the affected members from five independent LD families. Although we have not excluded the defects in the 
regulatory regions of the genes, or hemizygous deletions for the EPM2A exons, it is likely that these families might 
harbor mutations in the third but yet to be identified locus for LD. Presence of a third locus for LD has been  
proven for other populations (Chan et al., 2004; Gomez-Abad et al., 2005; Singh et al., 2005). A search for a novel 
disease associated locus in these families is being initiated. 
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Figure 4 : Protein extracts of COS-7 cells transiently transfected with expression constructs encoding the 
wild-type or the L310W mutant laforin with C-terminal Myc tag, as indicated, was immunoblotted. Anti-Myc 
antibody detected a single band at ~38 kDa range (arrow) both for the wild-type and the mutant laforin (a). 
Co-localization of laforin with ribosomes (b). COS-7 cells that had been transiently transfected with 
expression constructs encoding the wild-type or the mutant laforin were double stained with anti-Myc antibody 
or anti-ribosomal P antigen antibody (ribosomal marker) as indicated. Note the formation of perinuclear 
aggregate-like structures for the mutant laforin as against the reticular staining observed for the wild-type 
laforin. Nucleus was stained with DAPI. Scale bar, 10 µm. 
 
One of the most interesting aspects of the present study is the identification and functional characterization of 
the novel EPM2A mutation, c.929T>G, resulting in the amino acid conversion L310W. This missense mutation, 
which is predicted to affect only one of the two known isoforms of the laforin protein, dramatically affects the 
localization pattern of the mutant laforin-331. Unlike the wild-type, the laforin mutant L310W forms perinuclear 
aggregates, resembling various other mutations of laforin characterized in one of our previous studies (Mittal et al., 
2007). All such mutants formed perinuclear aggregates that were positive for ubiquitin tags, suggesting that they 
were misfolded proteins targeted for degradation using the ubiquitin-proteasome pathway (Ganesh et al., 2002; 
Mittal et al., 2007). Although we have not tested the phosphatase activity for the L310W mutant laforin, our cell 
biological observations suggest that, due to the cytoplasmic aggregation – possibly because of the misfolding – the 
mutant form might not be able to interact with its substrate hence the substrate would remain hyperphosphorylated. 
Since the physiological substrates for laforin is yet to be identified, this hypothesis however could not be tested. 
Nonetheless, our observations that the effect of this mutation is restricted to only one of the two isoforms of laforin 
strengthen an earlier suggestion that the loss of function of the cytoplasmic isoform of laforin results in the LD 
pathology (Ianzano et al., 2004). Our study also suggests that the two laforin isoforms have distinct functional 
roles, and that the nuclear isoform would not be able to compensate for the loss of the cytoplasmic isoform. 
Whether the converse would be true? Since mutations that exclusively affect the nuclear isoform are yet to be 
identified, it is unclear as of now as to whether or not the nuclear isoform could be involved in the LD pathology. 
It must however be noted that the cytoplasmic laforin is known to form functional dimers (Liu et al., 2006), and 
therefore the two isoform could possibly make “heterodimers” that show differential affinity for the substrates. 
With the identification of the L310W mutation, our study nevertheless underscores the importance of the 
cytoplasmic isoform in the LD pathology. L310W is only the second such mutation – the other one being Q319fs 
reported by Ianzano and colleagues (2004). 
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Figure 5 : Western blot analysis of whole-cell lysates derived 
from COS-7 cells expressing the wild-type (WT), the mutant (as 
indicated) malin–GFP chimeric proteins, or the GFP protein 
(GFP). The GFP is tagged to the amino-terminal end of the malin 
protein. 
 
Malin is an E3 protein ubiquitin ligase (Gentry et al., 2005; Lohi et al., 2006; Mittal et al., 2007). Functional 
characterizations of several LD associated mutations in the NHLRC1 gene have revealed diverse impact on the 
functional properties on malin. These include loss of ligase activity (Gentry et al., 2005), and loss of interaction 
with the laforin (Gentry et al., 2005). A recent study, from our group, has established that smaller deletions and 
missense mutations dramatically alter the subcellular localization of malin (Mittal et al., 2007). Curiously, a 
majority of the mutations affecting the NHL repeat domain have resulted in the aggregation of malin into 
“aggresomes”, a pericentrosomal cytoplasmic structures into which aggregated, ubiquitinated, misfolded proteins 
are known to be sequestered (Johnston et al., 1998). Indeed, such aggregate-prone malin mutants have shown to be 
positive for ubiquitin, proteasome and gamma-tubulin, suggesting that the mutants were misfolded proteins set for 
degradation (Mittal et al., 2007). In order to extend such a structure-function study and also to understand the sub-
domains of malin involved distinct cellular functions, we have generated mammalian expression constructs for 
malin having six different mutations identified in the Indian population. Unlike our previous observations, three of 
the mutation tested in the present study targeted the mutant protein to the nucleus. None of these mutations appear 
to have produced any NLS-like sequence. It is therefore unclear as of now as to how even subtle mutations might 
change the localization pattern of a protein which is predominantly cytoplasmic in nature. It is of interest to note 
that similar mutations in laforin also altered its subcellular localization and targeted it to the nucleus (Ganesh et al., 
2002). It would therefore be of interest to check whether these mutations abolish its affinity towards laforin or not. 
Not all mutations tested however resulted in the nuclear localization of mutant malin. For example, two mutations 
did not show any difference in localization as compared to the wild-type. Curiously, the catalytically inactive C26S 
mutant of malin was known to have a wild-type like subcellular expression pattern (Mittal et al., 2006). Since 
S22R falls close to the RING domain, it is tempting to suggest that this mutation could perhaps affect the catalytic 
activity of malin. As was shown previously, the NHL mutant malin L279P formed large perinuclear aggregates 
suggesting that it is a misfolded protein set for degradation. It should be noted however that the observations made 
in the present study were based on overexpression of mutant proteins in a fibroblast cell line and were not 
confirmed for the endogenous defective proteins expressing in the brain or other affected tissues. The observed 
difference therefore could be due to the “artificial” cell culture conditions. Nonetheless, the distinct and interesting 
differences observed for the individual mutant proteins, and absence of any aggresome-like structure for the wild-
type forms, strongly suggest the influence LD-associated mutations on the subcellular targeting of proteins bearing 
them. Pending such confirmatory studies on the endogenous mutant forms, our results are clear enough to suggest 
that alterations in the subcellular localization of LD proteins may underlie the molecular basis of loss of malin or 
laforin function for these mutations. Clearly, structural studies would provide insights into the effect of mutations 
on conformational changes of the resulting protein. 
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Figure 6 (previous page) : Effect of LD-associated mutations on subcellular localization of malin. 
Representative figures for the subcellular distribution of GFP-tagged wild-type malin or its mutants, as 
indicated, under transient expression conditions in COS-7 cells. As reported earlier (Mittal et al, 2007), wild 
type malin showed reticular staining that co-localized with the marker for the ribosomal marker. While the 
mutant S22R showed very similar localization as that of wild-type form, the mutant L279P formed 
perinuclear aggresome-like structures. Overlays of each set include DAPI staining. Scale bar, 10 µm. 
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